Literature DB >> 10851049

Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice.

D E Levy1, D G Gilliland.   

Abstract

Stat proteins are latent transcription factors activated by tyrosine phosphorylation downstream of cytokine and growth factor receptors and have been implicated in a variety of cell growth regulatory pathways. Constitutive phosphorylation has also been observed in various transformed cell line and in primary malignant tissue, suggesting that Stat protein activation may contribute to the transformed phenotype. One method to distinguish between a causative role in malignancy as opposed to bystander phosphorylation from the increased tyrosine phosphorylation that accompanies transformation is to investigate cell growth and malignancy in the absence of particular Stat proteins using targeted gene disruptions in transgenic mice. Such studies show that Stat1 primarily mediates growth inhibitory signals and contributes to the host rejection of tumors, and that its activation in transformed cells is not necessary for malignancy. Activation of Stat5 can be both necessary and sufficient for malignant transformation, and single Stat5-target genes have been identified that are critical for heightened proliferation. Nonetheless, some malignancies that are characterized by constitutively phosphorylated Stat5 are not altered by the loss of Stat5 protein. Its role in these cases may be redundant with other transforming events that are in themselves sufficient to cause disease, rendering tyrosine phosphorylation of Stat5 unnecessary in these transformed cells. Oncogene (2000).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10851049     DOI: 10.1038/sj.onc.1203480

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  24 in total

Review 1.  What does Stat3 do?

Authors:  David E Levy; Chien-kuo Lee
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

Review 2.  Antitumour actions of interferons: implications for cancer therapy.

Authors:  Belinda S Parker; Jai Rautela; Paul J Hertzog
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

3.  8p12 stem cell myeloproliferative disorder: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathways.

Authors:  G Guasch; V Ollendorff; J P Borg; D Birnbaum; M J Pébusque
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

4.  Expression of the serotonin receptor 2B in uveal melanoma and effects of an antagonist on cell lines.

Authors:  Cindy Weidmann; Julie Bérubé; Léo Piquet; Arnaud de la Fouchardière; Solange Landreville
Journal:  Clin Exp Metastasis       Date:  2018-04-25       Impact factor: 5.150

Review 5.  STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.

Authors:  K A Dorritie; J A McCubrey; D E Johnson
Journal:  Leukemia       Date:  2013-06-25       Impact factor: 11.528

Review 6.  The functions of signal transducers and activators of transcriptions 1 and 3 as cytokine-inducible proteins.

Authors:  Hyeonjoo Cheon; Jinbo Yang; George R Stark
Journal:  J Interferon Cytokine Res       Date:  2010-12-19       Impact factor: 2.607

Review 7.  The role of prolactin in mammary carcinoma.

Authors:  Charles V Clevenger; Priscilla A Furth; Susan E Hankinson; Linda A Schuler
Journal:  Endocr Rev       Date:  2003-02       Impact factor: 19.871

8.  Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells.

Authors:  Gregory B Lesinski; Jason M Zimmerer; Melanie Kreiner; John Trefry; Matthew A Bill; Gregory S Young; Brian Becknell; William E Carson
Journal:  BMC Cancer       Date:  2010-04-14       Impact factor: 4.430

9.  Suppression of STAT5A and STAT5B chronic myeloid leukemia cells via siRNA and antisense-oligonucleotide applications with the induction of apoptosis.

Authors:  Burçin Tezcanlı Kaymaz; Nur Selvi; Aysun Adan Gokbulut; Cağdaş Aktan; Cumhur Gündüz; Güray Saydam; Fahri Sahin; Vildan Bozok Cetintaş; Yusuf Baran; Buket Kosova
Journal:  Am J Blood Res       Date:  2013-01-17

10.  Bortezomib pre-treatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cells.

Authors:  Gregory B Lesinski; Kristen Benninger; Melanie Kreiner; Megan Quimper; Gregory Young; William E Carson
Journal:  Cancer Immunol Immunother       Date:  2009-04-26       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.